72197
神经氨酸酶 来源于霍乱弧菌
≥1.5 U/mL, specific activity ≥ 1.5U/mg protein
别名:
受体破坏酶, 唾液酸酶, 神经氨酸苷酶
生物来源
Vibrio cholerae
表单
liquid
比活
≥1.5 U/mg protein
浓度
≥1.5 U/mL
密度
1.00 g/mL at 20 °C
储存温度
2-8°C
正在寻找类似产品? 访问 产品对比指南
应用
神经氨酸酶被用作糖缀合物分布和底物特异性研究的细胞表面探针。
其他说明
1 U corresponds to the amount of enzyme which releases 1 μmol N-acetylneuraminic acid per minute at pH 4.5 and 37 °C (Neu5Acα(2-3,6)Galβ(1-4)Glc as substrate)
As a cell-surface probe of glycoconjugate distribution; Substrate specificity studies
警示用语：
Danger
危险声明
预防措施声明
危险分类
Resp. Sens. 1
储存分类代码
11 - Combustible Solids
WGK
WGK 1
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
Eyeshields, Gloves, type N95 (US)
法规信息
高风险级别生物产品--病毒，疫苗等
此项目有
A K Shukla et al.
Analytical biochemistry, 158(1), 158-164 (1986-10-01)
A rapid and sensitive assay by high-performance liquid chromatography for determination of the activity and substrate specificity of sialidase (EC 3.2.1.18) and N-acetylneuraminate lyase (EC 4.1.3.3) is described. Sialic acids were separated on a strong anion-exchange resin using 0.75 mM
Bo Ram Kim et al.
Journal of enzyme inhibition and medicinal chemistry, 33(1), 1256-1265 (2018-08-22)
Sialidases are key virulence factors that remove sialic acid from the host cell surface glycan, unmasking receptors that facilitate bacterial adherence and colonisation. In this study, we developed potential agents for treating bacterial infections caused by Streptococcus pneumoniae Nan A
S W Whiteheart et al.
Analytical biochemistry, 163(1), 123-135 (1987-05-15)
Rat liver beta-galactoside alpha-2,6-sialyltransferase and Vibrio cholerae sialidase were used, in conjunction with CMP-N-acetyl-[3H]neuraminic acid, to probe the glycoconjugate distribution, sialylation state, and level of penultimate Gal beta 1-4GlcNAc residues on the surfaces of murine thymic lymphocytes. We report a
Rodolfo Ocadiz-Delgado et al.
BMC infectious diseases, 13, 20-20 (2013-01-19)
In April 2009, public health surveillance detected an increased number of influenza-like illnesses in Mexico City's hospitals. The etiological agent was subsequently determined to be a spread of a worldwide novel influenza A (H1N1) triple reassortant. The purpose of the
Charles R Beck et al.
Influenza and other respiratory viruses, 7 Suppl 1, 14-24 (2013-02-12)
The objectives of this study were to: (1) reflect on key stages in the discovery, development and pre-pandemic use of neuraminidase inhibitors (NAIs), (2) summarise the evidence of NAI effectiveness for treatment and prophylaxis of seasonal influenza prior to the
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持